Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
YBX1 promotes type H vessel–dependent bone formation in an m5C-dependent manner
Yu-Jue Li, … , Sheng Deng, Ye Xiao
Yu-Jue Li, … , Sheng Deng, Ye Xiao
Published February 22, 2024
Citation Information: JCI Insight. 2024;9(4):e172345. https://doi.org/10.1172/jci.insight.172345.
View: Text | PDF
Research Article Angiogenesis Bone biology

YBX1 promotes type H vessel–dependent bone formation in an m5C-dependent manner

  • Text
  • PDF
Abstract

RNA-binding proteins (RBPs) interact with RNA and ubiquitously regulate RNA transcripts during their life cycle, playing a fundamental role in the progression of angiogenesis-related diseases. In the skeletal system, endothelium-dependent angiogenesis is indispensable for bone formation. However, the role of RBPs in endothelium-dependent bone formation is unclear. Here, we show that RBP–Y-box-binding protein 1 (YBX1) was strongly reduced in the bone vasculature of ovariectomy (OVX) mice. Endothelial cell–specific deletion of Ybx1 impaired CD31-high, endomucin-high (CD31hiEMCNhi) endothelium morphology and resulted in low bone mass whereas Ybx1 overexpression promoted angiogenesis-dependent osteogenesis and ameliorated bone loss. Mechanistically, YBX1 deletion disrupted CD31, EMCN, and bone morphogenetic protein 4 (BMP4) stability in an m5C-dependent manner and blocked endothelium-derived BMP4 release, thereby inhibiting osteogenic differentiation of bone mesenchymal stromal cells. Administration of recombinant BMP4 protein restored impaired bone formation in Ybx1 deletion mice. Tail vein injection of CD31-modified polyethylene glycol–poly (lactic-co-glycolic acid) carrying sciadopitysin, a natural YBX1 agonist, pharmacologically partially reversed CD31hiEMCNhi vessels’ decline and improved bone mass in both OVX and aging animals. These findings demonstrated the role of RBP-YBX1 in angiogenesis-dependent bone formation and provided a therapeutic approach for ameliorating osteoporosis.

Authors

Yu-Jue Li, Qi Guo, Ming-Sheng Ye, GuangPing Cai, Wen-Feng Xiao, Sheng Deng, Ye Xiao

×

Figure 6

Polyethylene glycol–poly (lactic-co-glycolic acid) nanoparticles carrying sciadopitysin enhance angiogenesis-dependent bone formation in OVX mice.

Options: View larger image (or click on image) Download as PowerPoint
Polyethylene glycol–poly (lactic-co-glycolic acid) nanoparticles carryin...
(A) The molecular structure of sciadopitysin (left) and the optimized binding modes with mouse YBX1 (right). (B) CCK8 assay analysis of the HUVECsʼ viability after treating with different concentrations of sciadopitysin. n = 6 independent experiments. (C) Western blotting analysis of BMP4, EMCN, CD31, and YBX1 protein levels in HUVECs treated with sciadopitysin. n = 3 independent experiments. (D) Schematic diagram of treating OVX mice with sciadopitysin. (E and F) Representative μCT images (E) and quantitative μCT analysis (F) of trabecular bone microarchitecture of femora. (G and H) Immunohistochemical staining and quantification of Ocn staining and TRAP staining in trabecular bone surfaces of femora. Scale bar, 50 μm and 100 μm. (I and J) FACS analysis dot plot (I) and quantification (J) of CD31hiEMCNhi ECs from femora and tibia. (K–O) Representative images and quantitation (N and O) of CD31- (green) and EMCN- (red) immunostained (K), BMP4- (green) and CD31- (red) immunostained (L), and VEGFA- (green) and Osterix+- (green) immunostained (M) tibia. n = 8 mice in each group. Scale bar, 200 μm. n = 2 independent experiments. Data are shown as the mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 by 1-way ANOVA.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts